These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38822123)

  • 1. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.
    Kato H; Shiraishi C; Hagihara M; Mikamo H; Iwamoto T
    Sci Rep; 2024 May; 14(1):12519. PubMed ID: 38822123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database.
    Li H; Zhang M; Jiao X; Zhu Y; Liu Y; Zeng L; Wang H; Zhang L; Zhang W; Zhang L
    Sci Rep; 2023 Mar; 13(1):4475. PubMed ID: 36934109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole-associated visual disturbances and hallucinations.
    Bayhan GI; Garipardic M; Karaman K; Akbayram S
    Cutan Ocul Toxicol; 2016 Mar; 35(1):80-2. PubMed ID: 25799212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole-related visual adverse events.
    Jiang YK; Wang RY; Wang X; Zhao HZ; Zhou LH; Huang LP; Yip CW; Cheng JH; Que CX; Jiang C; Zhu LP
    Mycoses; 2020 Jun; 63(6):579-587. PubMed ID: 32222082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies.
    Sakurada H; Yasuhara K; Kato K; Asano S; Yoshida M; Yamamura M; Tachi T; Teramachi H
    Pharmazie; 2016 Nov; 71(11):660-664. PubMed ID: 29441972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
    Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
    Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration.
    Woods RH
    Curr Drug Saf; 2024; 19(2):261-267. PubMed ID: 37526182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
    Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
    Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early dopaminergic drug-induced hallucinations in parkinsonian patients.
    Goetz CG; Vogel C; Tanner CM; Stebbins GT
    Neurology; 1998 Sep; 51(3):811-4. PubMed ID: 9748031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.
    Meco G; Alessandria A; Bonifati V; Giustini P
    Lancet; 1994 May; 343(8909):1370-1. PubMed ID: 7514254
    [No Abstract]   [Full Text] [Related]  

  • 15. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
    Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
    Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex visual hallucinations, presumably due to subarachnoid hemorrhage, treated successfully with risperidone.
    Spiegel DR; Petersen T
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):E44. PubMed ID: 21948927
    [No Abstract]   [Full Text] [Related]  

  • 17. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    Zhang KW; Reimers MA; Calaway AC; Fradley MG; Ponsky L; Garcia JA; Cullen J; Baumann BC; Addison D; Campbell CM; Ghosh AK; Lenihan DJ; Desai NR; Weintraub N; Guha A
    J Urol; 2021 Sep; 206(3):613-622. PubMed ID: 33872049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.